Literature DB >> 33904053

COVID 19 infection associated with thrombotic thrombocytopenic purpura.

Gaurav Dhingra1, Manideepa Maji2, Saikat Mandal3, Sudeep Vaniyath1, Gita Negi4, Uttam Kumar Nath1.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) which can cause significant mortality is a thrombotic microangiopathy due to deficiency of VWF cleaving protease ADAMTS13 and as per medical literature there are examples that TTP can be caused by COVID 19 infection. A 35 years old female after admission with right sided weakness and slurring of speech was found to be COVID positive and diagnosed as a case of TTP. Patient had absent ADAMTS13 level on day 1. Treatment was started with therapeutic plasma exchange (TPE) later injection Vincristine and Rituximab was given after 4th TPE as it was suspected as refractory case. Finally patient received 16 TPE procedures with cryo poor plasma as exchange fluid and gradually her platelet count started to maintain normal and she was discharged. Specific management and such association of this type of cases need to be studied more judiciously.

Entities:  

Keywords:  Covid 19; Therapeutic plasma exchange; Thrombosis; Thrombotic thrombocytopenic purpura; Vincristine in TTP

Year:  2021        PMID: 33904053     DOI: 10.1007/s11239-021-02452-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  7 in total

1.  Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor.

Authors:  Nobuharu Kosugi; Yuya Tsurutani; Ayami Isonishi; Yuji Hori; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Intern Med       Date:  2010-04-01       Impact factor: 1.271

2.  Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature.

Authors:  Alyssa Ziman; Michael Mitri; Ellen Klapper; Samuel H Pepkowitz; Dennis Goldfinger
Journal:  Transfusion       Date:  2005-01       Impact factor: 3.157

3.  Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2.

Authors:  Albert Huisman; Robert Beun; Maaike Sikma; Jan Westerink; Nuray Kusadasi
Journal:  Int J Lab Hematol       Date:  2020-05-22       Impact factor: 2.877

4.  Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients.

Authors:  Mario Bazzan; Barbara Montaruli; Savino Sciascia; Domenico Cosseddu; Claudio Norbiato; Dario Roccatello
Journal:  Intern Emerg Med       Date:  2020-06-18       Impact factor: 3.397

5.  Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia.

Authors:  Chris Lopez; Jeremy Kim; Apurva Pandey; Ted Huang; Thomas G DeLoughery
Journal:  Br J Haematol       Date:  2020-05-22       Impact factor: 6.998

6.  COVID-19-associated immune thrombocytopenia.

Authors:  Gienke Bomhof; Pim G N J Mutsaers; Frank W G Leebeek; Peter A W Te Boekhorst; Johannes Hofland; F Nanne Croles; A J Gerard Jansen
Journal:  Br J Haematol       Date:  2020-06-08       Impact factor: 8.615

7.  The ADAMTS13-von Willebrand factor axis in COVID-19 patients.

Authors:  Ilaria Mancini; Luciano Baronciani; Andrea Artoni; Paola Colpani; Marina Biganzoli; Giovanna Cozzi; Cristina Novembrino; Massimo Boscolo Anzoletti; Valentina De Zan; Maria Teresa Pagliari; Roberta Gualtierotti; Stefano Aliberti; Mauro Panigada; Giacomo Grasselli; Francesco Blasi; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-12-18       Impact factor: 16.036

  7 in total
  7 in total

1.  Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.

Authors:  Teresa Marta Cardesa-Salzmann; Bernhard Stephan; Arne Simon; Rhoikos Furtwängler; Dominik Schöndorf; Sabine Heine; Eyad Torfah; Margaux Lux; Sonja Meyer; Norbert Graf
Journal:  Clin Case Rep       Date:  2022-05-20

2.  Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19.

Authors:  Kristina Zguro; Margherita Baldassarri; Francesca Fava; Giada Beligni; Sergio Daga; Roberto Leoncini; Lucrezia Galasso; Michele Cirianni; Stefano Rusconi; Matteo Siano; Daniela Francisci; Elisabetta Schiaroli; Sauro Luchi; Giovanna Morelli; Enrico Martinelli; Massimo Girardis; Stefano Busani; Saverio Giuseppe Parisi; Sandro Panese; Carmelo Piscopo; Mario Capasso; Danilo Tacconi; Chiara Spertilli Raffaelli; Annarita Giliberti; Giulia Gori; Peter D Katsikis; Maria Lorubbio; Paola Calzoni; Agostino Ognibene; Monica Bocchia; Monica Tozzi; Alessandro Bucalossi; Giuseppe Marotta; Simone Furini; Alessandra Renieri; Chiara Fallerini
Journal:  Viruses       Date:  2022-05-29       Impact factor: 5.818

3.  Coronavirus Disease 2019-Associated Thrombotic Microangiopathy.

Authors:  Marija Malgaj Vrecko; Zeljka Veceric-Haler
Journal:  J Hematol       Date:  2022-08-30

Review 4.  Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.

Authors:  Xin Xu; Yao Feng; Yitong Jia; Xiao Zhang; Long Li; Xuesong Bai; Liqun Jiao
Journal:  Thromb Res       Date:  2022-08-18       Impact factor: 10.407

Review 5.  COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review.

Authors:  Haseeb Chaudhary; Usama Nasir; Khezar Syed; Maria Labra; Christopher Reggio; Ansar Aziz; Parin Shah; Roopika Reddy; Navdeep Sangha
Journal:  Hematol Rep       Date:  2022-08-02

6.  Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.

Authors:  Fei Fang; Brandon Tse; Katerina Pavenski
Journal:  BMJ Case Rep       Date:  2022-07-28

Review 7.  Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.

Authors:  Marija Malgaj Vrečko; Andreja Aleš Rigler; Željka Večerić-Haler
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.